BioMarin Pharmaceutical Inc. (BMRN) Balance Sheet
BMRN balance sheet, 2025
December 31, 2025 · U.S. dollars$7.59B assets = $1.51B liabilities + $6.09B equity
Both columns are drawn to the same scale: what BMRN owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BMRN financial health
Descriptive bands, not a rating. Fiscal 2025.
BMRN balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $4.02B2016 | $7.59B2025 | +7.3%/yr | |
| Total liabilities | $1.26B2016 | $1.51B2025 | +2.0%/yr | |
| Shareholders’ equity | $2.77B2016 | $6.09B2025 | +9.2%/yr | |
| Cash & short-term investments | $789.7M2016 | $1.56B2025 | +7.9%/yr | |
| Total debt | $683.2M2016 | $642.9M2025 | −0.7%/yr | |
| Net cash (debt) | $106.4M2016 | $917.7M2025 | +$811.3M | |
| Working capital | $982.5M2016 | $3.19B2025 | +$2.2B | |
| Book value per share | $16.642016 | $30.842025 | +7.1%/yr | |
| Current ratio | 3.242016 | 5.212025 | +1.97 | |
| Debt / equity | 0.252016 | 0.112025 | −0.14 | |
| Shares outstanding | 166.2M2016 | 197.4M2025 | +1.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BMRN assets
BMRN liabilities and equity
BMRN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BMRN balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $1.56B | $1.14B | $1.07B | $1.29B | $1.01B | $1.07B | $753.8M | $1.08B | $1.40B | $789.7M |
| Cash & equivalents | $1.31B | $942.8M | $755.1M | $724.5M | $587.3M | $649.2M | $437.4M | $494.0M | $598.0M | $408.3M |
| Short-term investments | $248.9M | $194.9M | $318.7M | $567.0M | $426.6M | $416.2M | $316.4M | $590.3M | $797.9M | $381.3M |
| Receivables | $908.2M | $660.5M | $633.7M | $461.3M | $373.4M | $448.4M | $377.4M | $342.6M | $261.4M | $215.3M |
| Inventory | $1.30B | $1.23B | $1.11B | $894.1M | $776.7M | $698.5M | $680.3M | $530.9M | $475.8M | $355.1M |
| Other current assets | $185.8M | $201.5M | $141.4M | $104.5M | $110.4M | $129.9M | $130.7M | $98.4M | $74.0M | $61.7M |
| Total current assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B |
| Property, plant & equipment (net) | $952.5M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $948.7M | $896.7M | $798.8M |
| Goodwill & intangible assets | $410.0M | $451.5M | $490.9M | $534.8M | $584.9M | $613.5M | $653.6M | $688.8M | $714.5M | $750.8M |
| Long-term investments | $492.2M | $521.2M | $611.1M | $333.8M | $507.8M | $285.5M | $412.0M | $235.9M | $385.8M | $572.7M |
| Other non-current assets | $1.79B | $1.74B | $1.72B | $1.68B | $1.60B | $1.57B | $671.4M | $497.5M | $428.9M | $479.6M |
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B |
| Liabilities | ||||||||||
| Accounts payable | $312.8M | $235.4M | $315.5M | $231.2M | $193.0M | $191.4M | $241.0M | $207.6M | $166.6M | $191.4M |
| Short-term debt | $8.7M | $23.1M | $502.7M | $10.4M | $10.5M | $11.8M | $372.6M | — | $360.9M | $22.5M |
| Deferred revenue | — | $1.4M | $4.6M | $711,000 | $7.0M | $152,000 | $13.0M | $1.5M | — | — |
| Total current liabilities | $759.0M | $607.0M | $1.18B | $588.9M | $539.8M | $492.5M | $932.5M | $523.2M | $816.5M | $439.3M |
| Long-term debt | $597.2M | $595.1M | $593.1M | $1.08B | $1.08B | $1.08B | $486.2M | $830.4M | $813.5M | $660.8M |
| Lease obligations | $8.7M | $7.6M | $8.8M | $10.4M | $10.5M | $11.8M | $10.7M | — | — | — |
| Other long-term liabilities | $150.8M | $128.8M | $119.9M | $100.0M | $113.7M | $174.3M | $148.9M | $105.5M | $194.4M | $157.3M |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.73B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $192,000 | $191,000 | $189,000 | $186,000 | $184,000 | $182,000 | $180,000 | $178,000 | $176,000 | $173,000 |
| Retained earnings (deficit) | $154.2M | −$194.7M | −$621.6M | −$789.2M | −$925.7M | −$861.6M | −$1.72B | −$1.69B | −$1.64B | −$1.52B |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | −$13.5M | $61.7M | −$28.8M | −$3.9M | $14.4M | −$16.1M | $20.2M | $5.3M | −$23.0M | $12.8M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.11B | $3.12B | $2.97B | $2.81B | $2.77B |
| Key figures | ||||||||||
| Total debt | $642.9M | $649.5M | $1.10B | $1.09B | $1.09B | $1.09B | $858.8M | $830.4M | $1.17B | $683.2M |
| Net cash (debt) | $917.7M | $488.2M | −$21.9M | $198.1M | −$75.7M | −$21.5M | −$105.0M | $253.9M | $221.5M | $106.4M |
| Working capital | $3.19B | $2.63B | $1.78B | $2.16B | $1.73B | $1.85B | $1.01B | $1.53B | $1.39B | $982.5M |
| Tangible book value | $5.68B | $5.21B | $4.46B | $4.07B | $3.69B | $3.49B | $2.47B | $2.28B | $2.09B | $2.02B |
| Book value per share | $30.84 | $28.76 | $25.84 | $24.36 | $23.36 | $21.42 | $17.44 | $16.74 | $16.10 | $16.64 |
| Shares outstanding | 197.4M | 196.7M | 191.6M | 189.0M | 182.9M | 191.7M | 179.0M | 177.3M | 174.4M | 166.2M |
| Current ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.21 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
| Quick ratio | 3.25 | 2.96 | 1.45 | 2.98 | 2.57 | 3.07 | 1.21 | 2.73 | 2.03 | 2.29 |
| Debt / equity | 0.11 | 0.11 | 0.22 | 0.24 | 0.26 | 0.26 | 0.28 | 0.28 | 0.42 | 0.25 |
| Equity / assets | 80.2% | 81.0% | 72.4% | 72.2% | 71.1% | 70.2% | 66.6% | 67.0% | 60.6% | 68.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $874.0M | $2.22B | $1.56B | $1.48B | $1.43B | $1.27B | $1.14B | $930.4M | $1.22B | $1.05B | $1.07B | $1.13B |
| Cash & equivalents | $874.0M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $942.8M | $675.4M | $972.1M | $747.0M | $755.1M | $785.4M |
| Short-term investments | $0 | $0 | $248.9M | $227.7M | $218.3M | $223.5M | $194.9M | $255.0M | $252.2M | $299.6M | $318.7M | $340.4M |
| Receivables | $1.06B | $903.9M | $908.2M | $790.3M | $855.9M | $739.2M | $660.5M | $777.5M | $691.2M | $637.2M | $633.7M | $572.5M |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | $1.11B | $1.03B |
| Other current assets | $254.0M | $205.5M | $185.8M | $204.3M | $177.2M | $181.5M | $201.5M | $169.3M | $160.4M | $163.3M | $141.4M | $224.8M |
| Total current assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | $2.96B | $2.96B |
| Property, plant & equipment (net) | $990.0M | $958.1M | $952.5M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | $1.07B | $1.07B |
| Goodwill & intangible assets | $5.54B | $400.9M | $410.0M | $429.3M | $435.8M | $443.5M | $451.5M | $457.1M | $461.7M | $475.9M | $490.9M | $498.7M |
| Long-term investments | $0 | $0 | $492.2M | $512.9M | $508.6M | $506.7M | $521.2M | $562.0M | $557.1M | $620.6M | $611.1M | $548.0M |
| Other non-current assets | $1.23B | $2.63B | $1.79B | $1.78B | $1.68B | $1.70B | $1.74B | $1.73B | $1.74B | $1.73B | $1.72B | $1.69B |
| Total assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | $6.84B | $6.76B |
| Liabilities | ||||||||||||
| Accounts payable | $407.0M | $395.5M | $312.8M | $389.7M | $310.8M | $293.8M | $235.4M | $312.3M | $257.4M | $292.2M | $315.5M | $301.4M |
| Short-term debt | $674.3M | $9.3M | $8.7M | $7.6M | $7.7M | $6.3M | $7.6M | $8.1M | $505.5M | $502.9M | $502.7M | $502.7M |
| Deferred revenue | — | — | — | — | — | — | $1.4M | $2.3M | $1.9M | $5.2M | $4.6M | −$301.4M |
| Total current liabilities | $1.66B | $793.2M | $759.0M | $798.4M | $684.2M | $628.2M | $607.0M | $715.7M | $1.07B | $1.09B | $1.18B | $1.16B |
| Long-term debt | $3.53B | $1.43B | $597.2M | $596.7M | $596.2M | $595.6M | $595.1M | $594.6M | $594.1M | $593.6M | $593.1M | $592.6M |
| Lease obligations | $16.1M | $9.3M | $8.7M | $7.6M | $7.7M | $6.3M | $7.6M | $8.1M | $10.7M | $8.6M | $8.8M | $9.3M |
| Other long-term liabilities | $209.8M | $155.5M | $150.8M | $163.1M | $148.8M | $129.7M | $128.8M | $127.5M | $119.4M | $117.4M | $119.9M | $105.5M |
| Total liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | $1.89B | $1.86B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | −$11.0M | $193,000 | $192,000 | $192,000 | $192,000 | $192,000 | $191,000 | $191,000 | $190,000 | $190,000 | $189,000 | $188,000 |
| Retained earnings (deficit) | $304.5M | $259.7M | $154.2M | $200.8M | $231.5M | −$9.0M | −$194.7M | −$319.6M | −$425.7M | −$532.9M | −$621.6M | −$641.9M |
| Accumulated other comprehensive income | −$8.8M | −$4.2M | −$13.5M | −$33.9M | −$44.6M | $19.2M | $61.7M | $4.7M | $26.8M | −$1.0M | −$28.8M | $6.3M |
| Total shareholders' equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B |
| Key figures | ||||||||||||
| Total debt | $4.20B | $1.44B | $642.9M | $604.2M | $603.9M | $602.0M | $602.7M | $602.7M | $1.10B | $1.10B | $1.10B | $1.10B |
| Net cash (debt) | −$3.33B | $782.8M | $917.7M | $873.6M | $828.3M | $670.4M | $535.0M | $327.8M | $124.7M | −$50.0M | −$21.9M | $30.5M |
| Working capital | $2.31B | $3.81B | $3.19B | $3.06B | $3.12B | $2.84B | $2.63B | $2.34B | $2.19B | $1.90B | $1.78B | $1.79B |
| Tangible book value | $786.6M | $5.81B | $5.68B | $5.63B | $5.59B | $5.35B | $5.21B | $4.96B | $4.82B | $4.60B | $4.46B | $4.40B |
| Book value per share | $32.56 | $31.43 | $30.84 | $31.54 | $30.65 | $29.49 | $28.78 | $27.46 | $26.36 | $25.46 | $25.81 | $25.62 |
| Shares outstanding | 194.1M | 197.7M | 197.4M | 192.0M | 196.6M | 196.5M | 196.6M | 197.1M | 200.5M | 199.3M | 191.8M | 191.2M |
| Current ratio | 2.39 | 5.81 | 5.21 | 4.83 | 5.56 | 5.52 | 5.33 | 4.27 | 3.05 | 2.74 | 2.51 | 2.54 |
| Quick ratio | 1.16 | 3.94 | 3.25 | 2.84 | 3.34 | 3.20 | 2.96 | 2.39 | 1.79 | 1.55 | 1.45 | 1.46 |
| Debt / equity | 0.66 | 0.23 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.21 | 0.22 | 0.22 | 0.22 |
| Equity / assets | 53.9% | 72.3% | 80.2% | 79.5% | 80.8% | 81.1% | 81.0% | 79.0% | 74.8% | 73.8% | 72.4% | 72.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
BMRN financial position
At the end of fiscal 2025 (December 31, 2025), BioMarin Pharmaceutical had total assets of $7.6 billion (up 8.7% from a year earlier), total liabilities of $1.5 billion and shareholders' equity of $6.1 billion. It held $1.6 billion in cash and short-term investments against $642.9 million of debt, a net cash position of $917.7 million. Its current ratio was 5.21. In the latest quarter (ended June 30, 2026) total assets were $11.7 billion and equity $6.3 billion.
Related: BMRN income statement, BMRN cash flow statement, BMRN key metrics. See the BMRN stock overview for the latest quote and news.
BMRN balance sheet FAQ
What are BioMarin Pharmaceutical's total assets?
BioMarin Pharmaceutical reported total assets of $7.6 billion at the end of fiscal 2025 (December 31, 2025), compared with $7.0 billion a year earlier.
How much debt does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical had $642.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.11.
How much cash does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical held $1.6 billion in cash and short-term investments at the end of fiscal 2025; with $642.9 million of debt that is net cash of $917.7 million.
What is BioMarin Pharmaceutical's book value?
BioMarin Pharmaceutical's shareholders' equity (book value) was $6.1 billion at the end of fiscal 2025, or $30.84 per share.
What is BioMarin Pharmaceutical's current ratio?
BioMarin Pharmaceutical had current assets of $4.0 billion and current liabilities of $759.0 million, a current ratio of 5.21 (it can cover its short-term obligations).
How much goodwill does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical carried $410.0 million of goodwill and intangible assets, 5.4% of total assets, at the end of fiscal 2025.